2 / 2
allied
academies
Page 13
December 05-06, 2019 | Dubai, UAE
29
th
International Conference on
14
th
International Conference on
Nursing Education and Research
Cancer and Cancer Therapy
Joint Event
&
Journal of Medical Oncology and Therapeutics | Volume 4
N
SC-631570 is the very first proton anticancer preparation
and due to this after administration it accumulates in
tumors very fast that can be seen under the UV-light thanks
to its the autofluores- cence. Besides this preparation can
regenerate the immune systemandworks as a immunomodu-
lating agent. The selective effect of the NSC 631570 has been
confirmed by 120 universities and research centers in the
world. Until now this preparation has been tested on over 100
cancer cell lines and on 12 normal cell lines. The researchers
who conducted studies with the anti-cancer preparation
NSC-631570 concluded: “The anticancer drug NSC-631570
exerts its cytotoxic effects on both mouse and human breast
cancer cell lines in a dose and time dependent manner.
Weeks following NSC-631570 treatment, cells maintained a
reduced capacity to proliferate.”
In a controlled clinical study conducted at the University
Grodno (Grodno, Belarus), after the therapy with NSC-631570
the hardening of the tumor, a slight increase in the tumor size
(5-10%) andproliferationof connective tissueswereobserved.
The tumours appeared harder and slightly enlarged after NSC-
631570 therapy and were easier to detect by ultrasound or
radiological examination. Metastatic lymph nodes were also
hardened and sclerotic (fibrous). Tumours and metastatic
lymph nodeswere clearly demarcated fromhealthy tissue and
therefore easier to remove. Complications such as prolonged
lymphorrhoea (leakage of lymph onto the skin surface), skin
necrosis (death of skin tissue), suppuration of the wound and
pneumonia, all occurred in patients from the twoNSC-631570
groups at only half the rate that they appeared in patients
from the control group. Based on the results of this study
the scientists from Grodno recom- mended the use of NSC-
631570, at the higher dosage in all breast cancer operations.
Other parameters were also evaluated, e.g. hormones (T3, T4,
cortisol, progesterone, estradiol, prolactin), immune values
(lymphocytes, immune globulins, complement, phagocytic
activity, morphologic and cytochemical changes), amino acids
and their derivates in plasma and in the tumor tissue.
The effect of the NSC-631570 on the various parameters in
breast cancer patients have been studied. Best results were
achieved with higher dosage of NSC-631570. Almost every
patient noted the improvement of the general well-being,
sleep and appetite. During the surgery, the tumors as well
as involved lymph nodes were presented sclerotic and well
demarcated from the surrounding tissue. This alleviated the
surgical removal of the tumor considerably. In the tumor
tissue, increased concentration of the amino acid proline was
revealedindicatingaugmentedproductionofconnectivetissue
that demarcates the tumor from surrounding tissue. NSC-
631570 improved also the amino acid balance of patients.
Speaker Biography
Wassil Nowicky Dipl. Ing., Dr. techn., DDDr. h. c., Director of “Nowicky
Pharma” and President of the Ukrainian Anti-Cancer Institute (Vienna,
Austria). Inventor of the anti-cancer preparation on the basis of celandine
alkaloids “NSC-631570”. He is an author of over 300 scientific articles
dedicated to cancer research. Wassil Nowicky is a real member of the New
York Academy of Sciences, member of the European Union for applied
immunology and of the American Association for scientific progress,
honorary doctor of the Janka Kupala University in Hrodno, doctor “honoris
causa” of the Open international university on complex medicine in
Colombo, honorary member of the Austrian Society of a name of Albert
Schweizer. He has received the award for merits of National guild of
pharmacists of America. the award of Austrian Society of sanitary, hygiene
and public health services and others.
e:
dr.nowicky@yahoo.deWassil Nowicky
Nowicky Pharma/ Ukrainian Anti-Cancer Institute, Austria
Anti-Cancer preparation NSC-631570 (UKRAIN) and its efficacy in
Cancer treatment
J Med Oncl Ther| Volume 4